• Revelation Biosciences’ net loss widened 74% year over year to $3.32 million for the three months ended September 30, 2026.
• Operating expenses rose 74% year over year to $3.38 million.
• Cash and cash equivalents totaled $9.12 million at September 30, with funding expected to support operations into the second quarter of 2027.
• Selected a global contract research organization for an upcoming study evaluating Gemini in patients with acute kidney injury.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104979383) on November 05, 2026, and is solely responsible for the information contained therein.